Cronos Group

CRON

Market cap $988M

Marijuana stocks are getting some attention this week following new interest from President Donald Trump.

Cannabis stocks surged after Trump endorsed CBD for senior healthcare, citing its potential to revolutionize treatment and reduce healthcare costs. Shares of TLRY, CGC, CRON, and ACB soared double digits, with related ETFs MSOS and MJ also posting significant gains.

Cannabis stocks lit up Wall Street after Donald Trump backed a push to bring CBD under Medicare. The former president reposted a three-minute video from The Commonwealth Project, a campaign arguing that older Americans should have access to hemp-derived cannabidiol.

Video posted on Truth Social touts CBD as a ‘gamechanger' and promotes Medicaid coverage of CBD products

Tilray Brands surged nearly 20% and was up 36% after market open, while Canopy Growth jumped about 20% and Cronos Group rose 13%.

CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss what's behind the jump in cannabis stocks.

President Donald Trump posted a video on Truth Social on Sunday, promoting the potential health benefits of cannabis. Cannabis stocks lit up on Monday after Trump resurrected hopes for a change in federal drug policy.

Cannabis stocks once soared to billion-dollar valuations, but now trade at penny stock levels after the hype faded. 40 U.S. states allow medical marijuana, 24 permit recreational use, yet federal barriers still stifle growth.

Shares of pot companies advanced in early premarket trading on Monday following a social media post by U.S. President Donald Trump over the weekend that suggested potential health benefits from the use of cannabidiol.

The Canadian cannabis sector remains a focus for investors as September trading continues. Market leaders are working to expand operations while positioning for long-term growth. Meanwhile, the U.S. cannabis industry has surpassed $33 billion in annual sales, with forecasts expecting over $50 billion by 2030. These numbers highlight the global opportunity for Canadian companies with cross-border strategies. Recently, headlines reported new momentum in U.S. legalization talks. Lawmakers are debating the rescheduling of cannabis at the federal level, which could expand banking access and reduce tax burdens. This development has fueled optimism for both U.S. operators and Canadian firms with American interests. Consequently, investors are paying closer attention to valuations and growth potential this week.